Fact: there is a large basket of publicly-listed, single asset companies. Frankly, many biotechs w/ a pipeline are really single asset companies + 1) a filler pipeline with no real value or, 2) a pipeline w/ symmetric risk where the pipeline is worthless if the lead asset fails.
Jul 31, 2020 • 13 tweets • 3 min read
Hey everyone! I thought I would provide a update. Let’s cover a couple of points on the Phase 2 and then where we’re going from here. Thread 👇
First of all, the Phase 2 data. While surprised and disappointed on the topline miss, I think BLU-5937 shows consistent and clear activity in higher cough patients.
Mar 4, 2019 • 9 tweets • 4 min read
Why is $CMTA a big deal for Canadians? At $1B+, it's probably the 2nd largest #cdnbiotech cash exit ever. 2ND LARGEST EVER. Let's dive into that for a bit: investor.clementiapharma.com/news-releases/…
Canada's largest biotech cash exit is vaccine maker ID Biomedical at $1.4B. I've got a story about this one but will save it for another day. Great exit (including timing) by CEO Tony Holler!